Course Summary

Expiration Date: 07/13/2029

Antimicrobial resistance continues to outpace antibiotic development, underscoring the need for agents with novel mechanisms. Gepotidacin, approved by the U.S. Food and Drug Administration in 2025, is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV at binding sites distinct from those targeted by fluoroquinolones, providing activity against resistant uropathogens. Approved for uncomplicated urinary tract infections (uUTIs) in female patients aged 12 years and older, gepotidacin has demonstrated non-inferior efficacy to nitrofurantoin in the phase 3 EAGLE-2 and EAGLE-3 trials while maintaining activity against fluoroquinolone-resistant E. coli. This course reviews gepotidacin’s mechanism, pharmacology, clinical trial evidence, dosing, safety profile, and role in antimicrobial stewardship for the management of resistant uUTIs.

Course Format

Homestudy

Course Syllabus

  • Introduction
  • Mechanism and Pharmacologic Class
  • Indication and Clinical Use
  • Pharmacology and Drug Facts
    • Formulation and Dosage
    • Spectrum of Activity
    • Contraindications and Precautions
    • Adverse Effects
    • Patient Counseling Points
  • The Need for Innovation in Antibiotic Therapy
    • Economic and Research Challenges
  • Why Gepotidacin Is Different
    • Place in Therapy
    • Background
    • Methods
    • Results
    • Study Discussion
  • Summary

Authors

Richard Daniels, PharmD, BCPS

Richard “Cole” Daniels earned his Doctor of Pharmacy(PharmD) from the Skaggs School of Pharmacy at the University of Montana in 2018. Throughout pharmacy school he completed a 3-year internship at Community Medical Center in Missoula, Montana in which he gained valuable experience in an acute care setting. Cole currently serves as a psychiatric clinical staff pharmacist at the Montana State Hospital. He has over 11 years of pharmacy experience having worked in several settings including retail, acute care, and inpatient psychiatric care. Cole has a diverse set of interests. However, acute care medicine, infectious disease, pain management, and asthma/COPD are a primary focus of his at the Montana State Hospital. He obtained board certification as a certified pharmacotherapy specialist in the Spring of 2022.

Elisabeth Gordon, BScPharm, RPh

Elisabeth Gordon earned her BSc(Pharm) from the University of British Columbia in 2004. After graduation, she worked in community retail pharmacies on Vancouver Island, before returning to her rural hometown of Salmon Arm. In 2016 and 2017, Elisabeth trained with Pallium Canada and Victoria Hospice to enhance her knowledge of end-of-life-care and palliative services. She is a volunteer medical supervisor for T1DOutreach, a peer support platform for adults living with type 1 diabetes, and a member of a Canadian peer support group for adults living with Birdshot Uveitis. Elisabeth enjoys working in a small, fast-paced rural pharmacy where she brings compassion and empathy to her everyday practice.